Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Cancer × cabozantinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 66 Carcinoma, Hepatocellular 23 Prostatic Neoplasms 20 Neoplasm Metastasis 17 Neoplasms 15 Kidney Neoplasms 13 Carcinoma, Non-Small-Cell Lung 13 Neuroendocrine Tumors 8 Carcinoma, Medullary 8 Melanoma 7 Carcinoma, Transitional Cell 7 Brain Neoplasms 7 Urinary Bladder Neoplasms 6 Sarcoma 6 Osteosarcoma 6 Colorectal Neoplasms 6 Breast Neoplasms 6 Thyroid Neoplasms 5 Sarcoma, Ewing 5 Recurrence 5 Pancreatic Neoplasms 5 Clear-cell metastatic renal cell carcinoma 5 Carcinoma 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Multiple Myeloma 4 Lung Neoplasms 4 Urethral Neoplasms 3 Small Cell Lung Carcinoma 3 Liver Neoplasms 3

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 durvalumab 2 vinflunine 1 tremelimumab 1 niraparib 1 enfortumab vedotin 1 cabozantinib 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Radiotherapy 1 Paclitaxel 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Everolimus 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03425201 2024-12-31

NICARAGUA

Fundacion CRIS de Investigación para Vencer el Cáncer

Phase 1/2 Completed

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡